Supplementary Appendix
|
|
- Abraham Warren
- 6 years ago
- Views:
Transcription
1 Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Howard R, McShane R, Lindesay J, et al. Donepezil and memantine for moderate-to-severe Alzheimer s disease. N Engl J Med 2012;366:
2 Online Supplement 1. Details of minimisation algorithm... 2 Table S1: Allocation probabilities according to pattern of previous assignments Details of MMRM Model Sensitivity analyses to explore the effect of discontinuation from treatment Statistical Methods Results and Discussion... 5 Table S2. Estimates of treatment differences in smmse and BADLS after 52 weeks with 95% CI for continuing and discontinuing donepezil and between adding active memantine and adding memantine placebo Supplementary Tables... 7 Table S3. Difference in smmse and BADLS at each visit between patients discontinuing treatment and continuing on treatment Table S4. Estimate of average differences between trial arms in primary (smmse and BADLS) and secondary (NPI, DEMQOL-proxy and GHQ-12) outcomes over all time points with 95% CIs for the primary outcomes and 99% CIs for the secondary outcomes Table S5. Classification of Serious Adverse Events (SAEs) by treatment arm... 10
3 1. Details of minimisation algorithm The first 80 patients recruited to the DOMINO trial were randomly allocated to one of the four treatment groups using a prepared list of simple randomised allocations. The reason for this was to maintain allocation concealment before the start of the minimisation algorithm. Starting with the eighty-first patient treatment was allocated by minimising treatment imbalance across four stratifying factors and using probability ratios that will vary according to the patterns of imbalance across the four treatment groups. There are four stratification factors to be incorporated into the minimisation algorithm: centre (15 strata); age at randomisation (3 strata: <60y, 60 to 74y, 75y and above); duration of donepezil treatment at randomisation (2 strata: 3 to <6m, 6m and above; standardised Mini-Mental State Examination (smmse) score at randomisation (2 strata 5-9, 10-13). The algorithm initially simply summed the previous treatment allocations across the four strata matching the new patient. For example, if a new patient was from Newcastle, aged 60 to 74 years, has received donepezil for less than six months, and has a smmse score of 8, the total allocations to each of the four treatments would be summed for Newcastle, age 60 to 74 years, donepezil for less than six months, and smmse score of between 5 and 8, thereby providing four separate totals, one for each treatment group. Assignment of treatment was then weighted according to the pattern of the four totals as shown in Table S1, where A, B, C, and D represent the four treatment totals placed in a non-decreasing order. (When two treatment totals are equal their ordering is immaterial). Table S1: Allocation probabilities according to pattern of previous assignments Pattern Description Treatment A B C D A = B = C = D A = B = C < D A = B < C = D A = B < C < D A < B = C = D A < B = C < D A < B < C = D A < B < C < D All four totals equal Lowest three totals equal Two lowest equal, and two highest equal Two lowest equal Highest three totals equal Middle two totals equal Highest two totals equal All unequal
4 2. Details of MMRM Model The primary analyses of the primary outcomes and the continuous secondary outcomes were conducted using multilevel modelling repeated measures regression (MMRM) adjusted for baseline and the four minimisation factors (centre, age, duration of donepezil and smmse score prior to randomisation). All non-missing at every visit, irrespective of whether the patient was still on trial medication or had switched to open-label treatment, were included in this analysis and there was no imputation of missing. Several models were fit to explore the effect of interactions. For patient i=1,,291 at follow-up visit j=1 (6 weeks), 2 (18 weeks), 3 (30 weeks), 4 (52 weeks), the full model was fit first: y ij = β 0 y i0 + s i + v 0j + ζ j + β 1 d i + β 2 m i + β 3 d i m i + v 1j d i + v 2j m i + ε ij, where: o y ij is the outcome of patient i at follow-up visit j; o y i0 is the baseline outcome for patient i, β 0 is the parameter representing the effect of the baseline outcome in the model; o v 0j is the parameter representing of the effect at follow-up visit j (v 04 =0 by design); o d i and m i are the indicator variables for whether patient i was randomised to continue (d i =1) or discontinue donepezil (d i =0) and randomised to start active (m i =1) or placebo memantine (m i =0); o β 1, β 2 and β 3 are the parameters representing the effect of donepezil, memantine and the interaction between donepezil and memantine; o v 1j and v 2j are the parameters representing the interactions between follow-up visit j and each of donepezil and memantine (v 14 =v 24 =0 by design); o ζ j is the random effect parameter assumed to follow a multivariate normal distribution ζ j ~ MVN(0, Σ); o ε ij is the simple error term assumed to follow a normal distribution ε ij ~ N(0,σ 0 2 ). No three-way interaction terms were included in the model to avoid convergence problems. s i is the term representing the adjustment for randomisation stratification factors for patient i: s i = γ 0 + γ 11 x 11i + γ 12 x 12i + γ 2 x 2i + γ 3 x 3i + γ 41 x 41i + γ 42 x 42i + + γ 414 x 414i where: o x 11i and x 12i are indicator variables for the age of patient i: less than 60 years, 60 to less than 75 years, 75 years or over; o x 2i is the indicator variable for duration of previous donepezil at randomisation of patient i: less than six months, greater or equal to six months; o x 3i is the indicator variable for baseline smmse score for patient i: 5 to 9 (severe dementia), 10 to 13 (moderate dementia); o x 41i, x 42i,,x 413i,x 414i are 14 indicator variables for the 15 different study centres for patient i; o the γ s are nuisance parameters representing the effects of the various stratification factors (γ 0 is fixed effects constant term).
5 Different covariate structures for Σ were compared using the Akaike Information Criterion. The model did not converge when the unstructured covariance matrix was used. The chosen model therefore used an independent covariance matrix, Σ ij =0 for i j and Σ ii =σ i 2. The model was subsequently fit setting v 1j =v 2j =0 to estimate the average treatment effect during follow-up for the between arm comparisons (including the interaction) and also fit setting v 1j =v 2j =β 3 =0 to estimate the average effect of each of donepezil and memantine during follow-up. The models were fit using maximum likelihood estimation using the modified Newton-Raphson algorithm in Stata version The importance of individual terms in the models were evaluating using the Wald test. Further models were fit to evaluate whether the effect of donepezil and memantine on the primary outcomes differed by dementia severity (x 3i =1 for severe dementia and x 3i =0 for moderate dementia). The following model was fit (excluding the treatment interaction, setting β 3 =0): y ij = β 0 y i0 + s i + v 0j + ζ j + β 1 d i + β 2 m i + β 4 x 3i d i + β 5 x 3i m i + v 1j d i + v 2j m i + v 3j x 3i + v 4j x 3i d i + v 5j x 3i m i + ε ij, where: o β 4 and β 5 are the parameters representing the interactions between disease severity and each of donepezil and memantine; o v 3j is the parameter representing the interaction between follow-up visit j and dementia severity (v 34 =0 by design); o v 4j and v 5j are the parameters representing the three-way interactions between follow-up visit j, dementia severity and each of donepezil and memantine (v 44 =v 54 =0 by design). For both the smmse and BADLS, neither of the three-way interactions or the interaction between dementia severity and follow-up visit were significant at the 5% level and these terms were therefore dropped from the models. For both primary outcomes, the interactions between dementia severity and memantine was not significant at the 5% level, the same was true for the interaction between dementia severity and donepezil on BADLS. The interaction between donepezil and dementia severity was, however, significant on smmse showing that the effect of donepezil on smmse did differ by baseline dementia severity.
6 3. Sensitivity analyses to explore the effect of discontinuation from treatment 3.1. Statistical Methods Four different single imputation techniques were used: (1.) Imputing missing using a patient s last non-missing score (last observation carried forward - LOCF), (2.) Imputing after treatment discontinuation using a patient s last score before discontinuing treatment (treatment LOCF), (3.) Fitting a straight line to a patient s data before treatment discontinuation and imputing after discontinuation from the fitted line, (4.) Fitting an inverse exponential decline curve to a patient s data before treatment discontinuation and imputing after discontinuation from the fitted curve. The confidence intervals around the estimates using single imputation are artificially narrow as the false precision of the imputations has not been accounted for. (5.) Multiple imputation has been used to impute after discontinuation from treatment properly accounting for the artificial precision of the imputations. All stratification factors, the treatment, the visit week and the inverse exponential of the visit week are included in the imputation model. (6.) The primary analysis was repeated on a per protocol population defined as all patients having taken at least 70% of their treatment over the course of the trial, excluding any patients randomised in error or having taken open label donepezil or memantine concurrently with their study medication, and excluding any visits outside of the protocol-defined visit windows. (7.) The effect of donepezil and memantine was also evaluated using a simple unpaired t-test of the change in baseline as each visit Results and Discussion Patients in all treatment arms declined in cognitive function and activities of daily living over the course of the trial (Table S2). Imputation using LOCF underestimates the decline and therefore results in a bias in favour of the arm with the most drop-outs. Considerably more patients discontinued from treatment on the placebo arm and therefore TLOCF results in biased treatment effects that likely underestimate the true effects. Imputation assuming a linear or exponential decline is likely to be more appropriate than TLOCF, and both these analyses yield similar treatment estimates that are slightly smaller than those from the primary analysis. However, as shown in
7 Tables 4, patients who discontinue from treatment after 18 weeks have lower smmse and higher BADLS at the visit immediately prior to discontinuing. The observed case ITT analysis is therefore also an underestimate of the mean decline had all patients remained on treatment for the duration of the trial. No analysis can be considered to give uniformly unbiased treatment estimates but, with the exception of the results of the TLOCF analysis, the results are broadly consistent for each comparison suggesting the results of the primary analysis are robust estimates of the efficacy of donepezil and memantine in this patient population. Table S2. Estimates of treatment differences in smmse and BADLS after 52 weeks with 95% CI for continuing and discontinuing donepezil and between adding active memantine and adding memantine placebo smmse BADLS Endpoint and method of analysis Continue donepezil compared with discontinue Active memantine compared with Placebo Observed case ITT 1.9 (1.0, 2.8)* 0.7 (-0.2, 1.7) 1. LOCF 1.7 (0.9, 2.5)* 0.9 (0.1, 1.7)* Single 2. TLOCF 0.9 (0.1, 1.8)* 0.4 (-0.4, 1.2) imputation 3. Linear 1.2 (-0.1, 2.6) 0.5 (-0.8, 1.8) 4. Exponential 1.1 (-0.3, 2.4) 0.5 (-0.8, 1.9) 5. Multiple imputation 2.0 (0.9, 3.2)* 0.8 (-0.3, 2.0) 6. Per-protocol analysis 2.0 (0.8, 3.2)* 0.9 (-0.3, 2.1) 7. t-test change from baseline (mean / p-value) 1.57 / p= / p=0.096 Observed case ITT -2.9 (-4.9, -0.8)* -2.0 (-4.0, 0.1) 1. LOCF -2.5 (-4.3, -0.6)* -1.8 (-3.6, 0.1) Single 2. TLOCF -1.2 (-2.8, 0.5) -0.6 (-2.3, 1.1) imputation 3. Slope -3.2 (-6.3, -0.2)* -2.1 (-5.1, 1.0) 4. Exponential -2.6 (-5.7, 0.4) -1.7 (-4.8, 1.3) 5. Multiple imputation -3.2 (-5.3, -1.1)* -1.9 (-4.0, 0.2) 6. Per-protocol analysis -2.0 (-4.3, 0.3) -1.3 (-3.6, 1.0) 7. t-test change from baseline (mean / p-value) / p= / p=0.064 It is assumed that there is no interaction. These results relate to primary objectives 1 and 2. The asterisk (*) indicates the 95% CI excludes 0. The first row shows the estimates for the primary observed case ITT analysis from Table 3 for comparison.
8 4. Supplementary Tables Table S3. Difference in smmse and BADLS at each visit between patients discontinuing treatment and continuing on treatment. Baseline 6 week 18 week 30 week 6 week 18 week 30 week 52 week smmse BADLS Remain on trial treatment? Difference (95% Mean Difference (95% N Mean (SD) N CI), p-value (SD) CI), p-value Comparison of before withdrawal of trial treatment for patients still on treatment Remain on treatment (2.6) 0.7 (-0.5, 1.9) (9.1) -3.1 (-7.2, 1.0) Withdraw before 6 weeks (2.7) p= (8.7) p=0.136 Remain on treatment (4.2) 1.4 (0.1, 2.6) (9.4) -3.4 (-6.3, -0.6) Withdraw before 18 weeks (3.6) p= (10.0) p=0.094 Remain on treatment (4.5) 2.8 (1.2, 4.5) (9.6) -7.6 (-11.3, -4.0) Withdraw before 30 weeks (3.8) p= (11.1) p<0.001 Remain on treatment (4.3) 2.5 (0.8, 4.1) (10.0) -5.5 (-9.2, -1.8) Withdraw before 52 weeks (4.2) p= (8.0) p=0.005 Comparison of after withdrawal from treatment Remained on treatment (4.1) -3.1 (-5.3, -0.9) (9.6) 5.3 (0.1, 10.4) Withdrawn before 6 weeks 20 (14)* 5.9 (3.1) p= (14)* 34.1 (8.3) p=0.050 Remained on treatment (4.5) -2.8 (-4.3, -1.4) (10.2) 6.3 (3.0, 9.6) Withdrawn before 18 weeks 72 (44)* 5.1 (3.9) p= (44)* 38.1 (9.5) p=0.011 Remained on treatment (4.4) -3.7 (-4.9, -2.5) (9.8) 8.1 (5.2, 11.0) Withdrawn before 30 weeks 105 (60)* 3.8 (3.5) p< (60)* 40.0 (9.9) p<0.001 Remained on treatment (4.5) -3.3 (-4.6, -2.1) (9.3) 8.8 (6.1, 11.5) Withdrawn before 52 weeks 137 (63)* 2.5 (3.4) p< (64)* 43.6 (9.1) p<0.001
9 N is the number of patients in each case and the difference is between the two groups at each visit. The p-value is from the test that the difference is equal to 0, adjusted for treatment group. *This is the total number of patients withdrawing from treatment with the total number attending the visit and contributing a non-missing score in parentheses. Standardised Mini-Mental State Examination (smmse, range 0 to 30, higher indicate better cognitive function); Bristol Activities of Daily Living Scale (BADLS, range 0 to 60, higher indicate greater functional impairment).
10 Table S4. Estimate of average differences between trial arms in primary (smmse and BADLS) and secondary (NPI, DEMQOL-proxy and GHQ-12) outcomes over all time points with 95% CIs for the primary outcomes and 99% CIs for the secondary outcomes. smmse (95% CI) BADLS (95% CI) NPI (99% CI) DEMQOL-proxy (99% CI) GHQ-12 (99% CI) Continue donepezil compared with discontinue when placebo memantine is started 2.4 (1.5, 3.2)* -4.1 (-5.8, -2.4)* -1.2 (-6.0, 3.5) -2.4 (-6.6, 1.9) -0.5 (-1.3, 0.2) Continue donepezil compared with discontinue when active memantine is started 1.5 (0.6, 2.3)* -2.0 (-3.7, -0.3)* -3.4 (-8.2, 1.4) -0.9 (-5.2, 3.4) -0.6 (-1.3, 0.2) Active memantine compared with placebo when donepezil is tapered and discontinued 1.7 (0.8, 2.5)* -2.6 (-4.3, -0.8)* -2.9 (-7.8, 1.9) 0.5 (-3.9, 4.9) -0.5 (-1.2, 0.3) Active memantine compared with placebo when donepezil is continued 0.8 (-0.1, 1.6) -0.5 (-2.2, 1.2) -5.1 (-9.8, -0.3)* 2.0 (-2.3, 6.2) -0.5 (-1.3, 0.3) The asterisk (*) indicates that the 95% or 99% CI excludes 0.
11 Table S5. Classification of Serious Adverse Events (SAEs) by treatment arm. Taper and discontinue donepezil Add placebo Add memantine memantine Continue donepezil Add placebo memantine Add memantine Fall Respiratory tract infection Urinary tract infection Deterioration of AD Behavioural symptoms of AD Gastrointestinal Stroke Cardiac Dysphagia Psychosis Unknown (died) Venous embolus Cancer Syncope GI Bleed Social Other All SAEs Drug error Deaths A total of 188 SAEs were reported by 123 patients during follow-up. Where more than one of the same type of event was reported by a patient, only the first in included in the table. Total
Supplementary Online Content
Supplementary Online Content Atri A, Frölich L, Ballard C, et al. Effect of idalopirdine as adjunct to cholinesterase inhibitors on in cognition in patients with Alzheimer disease: three randomized clinical
More informationMonth/Year of Review: September 2013 Date of Last Review: February 2012
Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35, Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119 Copyright 2012 Oregon State University. All Rights
More informationCOMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP) POINTS TO CONSIDER ON MISSING DATA
The European Agency for the Evaluation of Medicinal Products Evaluation of Medicines for Human Use London, 15 November 2001 CPMP/EWP/1776/99 COMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP) POINTS TO
More informationNeurocognitive Disorders Research to Emerging Therapies
Neurocognitive Disorders Research to Emerging Therapies Edward Huey, MD Assistant Professor of Psychiatry and Neurology The Taub Institute for Research on Alzheimer s Disease and the Aging Brain Columbia
More informationSafinamide (Addendum to Commission A15-18) 1
IQWiG Reports Commission No. A15-41 Safinamide (Addendum to Commission A15-18) 1 Addendum Commission:A15-41 Version: 1.1 Status: 29 October 2015 1 Translation of addendum A15-41 Safinamid (Addendum zum
More informationCatherine A. Welch 1*, Séverine Sabia 1,2, Eric Brunner 1, Mika Kivimäki 1 and Martin J. Shipley 1
Welch et al. BMC Medical Research Methodology (2018) 18:89 https://doi.org/10.1186/s12874-018-0548-0 RESEARCH ARTICLE Open Access Does pattern mixture modelling reduce bias due to informative attrition
More informationCHL 5225 H Advanced Statistical Methods for Clinical Trials. CHL 5225 H The Language of Clinical Trials
CHL 5225 H Advanced Statistical Methods for Clinical Trials Two sources for course material 1. Electronic blackboard required readings 2. www.andywillan.com/chl5225h code of conduct course outline schedule
More informationThe comparison or control group may be allocated a placebo intervention, an alternative real intervention or no intervention at all.
1. RANDOMISED CONTROLLED TRIALS (Treatment studies) (Relevant JAMA User s Guides, Numbers IIA & B: references (3,4) Introduction: The most valid study design for assessing the effectiveness (both the benefits
More informationStrategies for handling missing data in randomised trials
Strategies for handling missing data in randomised trials NIHR statistical meeting London, 13th February 2012 Ian White MRC Biostatistics Unit, Cambridge, UK Plan 1. Why do missing data matter? 2. Popular
More informationRandomized Controlled Trial
Randomized Controlled Trial Training Course in Sexual and Reproductive Health Research Geneva 2016 Dr Khalifa Elmusharaf MBBS, PgDip, FRSPH, PHD Senior Lecturer in Public Health Graduate Entry Medical
More informationThe RoB 2.0 tool (individually randomized, cross-over trials)
The RoB 2.0 tool (individually randomized, cross-over trials) Study design Randomized parallel group trial Cluster-randomized trial Randomized cross-over or other matched design Specify which outcome is
More informationPSI Missing Data Expert Group
Title Missing Data: Discussion Points from the PSI Missing Data Expert Group Authors PSI Missing Data Expert Group 1 Abstract The Points to Consider Document on Missing Data was adopted by the Committee
More informationDonepezil and Memantine for Moderate-to-Severe Alzheimer s Disease
original article Donepezil and Memantine for Moderate-to-Severe Alzheimer s Disease Robert Howard, M.D., Rupert McShane, F.R.C.Psych., James Lindesay, D.M., Craig Ritchie, M.D., Ph.D., Ashley Baldwin,
More informationPer the study design and a limitation of this analysis, swabs were not tested for HPV types 6
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 SUPPLEMENTARY MATERIAL Progression, regression, and clearance of HPV6/11 infections Per the study design and a limitation of this analysis, swabs
More informationRecommendations for the Primary Analysis of Continuous Endpoints in Longitudinal Clinical Trials
STATISTICS 303 Recommendations for the Primary Analysis of Continuous Endpoints in Longitudinal Clinical Trials Craig H. Mallinckrodt, PhD Research Advisor, Lilly Research Laboratories, Eli Lilly and Company,
More informationWATCHMAN PROTECT AF Study Rev. 6
WATCHMAN PROTECT AF Study Rev. 6 Protocol Synopsis Title WATCHMAN Left Atrial Appendage System for Embolic PROTECTion in Patients with Atrial Fibrillation (PROTECT AF) Sponsor Atritech/Boston Scientific
More informationIan McKeith MD, F Med Sci, Professor of Old Age Psychiatry, Newcastle University
Ian McKeith MD, F Med Sci, Professor of Old Age Psychiatry, Newcastle University Design of trials in DLB and PDD What has been learnt from previous trials in these indications and other dementias? Overview
More informationBRL /RSD-101C0D/1/CPMS-704. Report Synopsis
Report Synopsis Study Title: A Randomized, Multicenter, 10-Week, Double-Blind, Placebo- Controlled, Flexible-Dose Study to Evaluate the Efficacy and Safety of Paroxetine in Children and Adolescents with
More informationSampling Weights, Model Misspecification and Informative Sampling: A Simulation Study
Sampling Weights, Model Misspecification and Informative Sampling: A Simulation Study Marianne (Marnie) Bertolet Department of Statistics Carnegie Mellon University Abstract Linear mixed-effects (LME)
More informationGreg Pond Ph.D., P.Stat.
Statistics for Clinical Trials: Basics of a Phase III Trial Design Greg Pond Ph.D., P.Stat. Ontario Clinical Oncology Group Escarpment Cancer Research Institute Department of Oncology, McMaster University
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Co-Primary Outcomes/Efficacy Variables:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationAdalimumab M Clinical Study Report Final R&D/16/0603
Methodology (Continued): The 70-day safety follow-up period started from the last dose of study drug, but was not required for any subject who initiated commercial Humira after study completion. Additional
More informationEU regulatory concerns about missing data: Issues of interpretation and considerations for addressing the problem. Prof. Dr.
EU regulatory concerns about missing data: Issues of interpretation and considerations for addressing the problem Prof. Dr. Karl Broich Disclaimer No conflicts of interest Views expressed in this presentation
More informationSYNOPSIS. Study center(s) This study was conducted in the United States (128 centers).
Drug product: Drug substance(s): Document No.: Edition No.: Study code: Date: SYMBICORT pmdi 160/4.5 µg Budesonide/formoterol SD-039-0725 17 February 2005 SYNOPSIS A Twelve-Week, Randomized, Double-blind,
More informationStudy No Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable(s):
Studies listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationSupplement for: CD4 cell dynamics in untreated HIV-1 infection: overall rates, and effects of age, viral load, gender and calendar time.
Supplement for: CD4 cell dynamics in untreated HIV-1 infection: overall rates, and effects of age, viral load, gender and calendar time. Anne Cori* 1, Michael Pickles* 1, Ard van Sighem 2, Luuk Gras 2,
More informationTreatment guidelines and health policy decisions
The Journal of Prevention of Alzheimer s Disease - JPAD Volume 2, Number 3, 2015 Post Hoc Evidence for an Additive Effect of Memantine and Donepezil: Consistent Findings from DOMINO-AD Study and Memantine
More informationContents. Version 1.0: 01/02/2010 Protocol# ISRCTN Page 1 of 7
Contents 1. INTRODUCTION... 2 2. STUDY SYNOPSIS... 2 3. STUDY OBJECTIVES... 2 3.1. Primary Objective... 2 3.2. Secondary Objectives... 2 3.3. Assessment of Objectives... 3 3.4. Change the Primary Objective
More informationAnalysis of Vaccine Effects on Post-Infection Endpoints Biostat 578A Lecture 3
Analysis of Vaccine Effects on Post-Infection Endpoints Biostat 578A Lecture 3 Analysis of Vaccine Effects on Post-Infection Endpoints p.1/40 Data Collected in Phase IIb/III Vaccine Trial Longitudinal
More informationRevised Cochrane risk of bias tool for randomized trials (RoB 2.0) Additional considerations for cross-over trials
Revised Cochrane risk of bias tool for randomized trials (RoB 2.0) Additional considerations for cross-over trials Edited by Julian PT Higgins on behalf of the RoB 2.0 working group on cross-over trials
More informationRandomization: Too Important to Gamble with
Randomization: Too Important to Gamble with A Presentation for the Delaware Chapter of the ASA Oct 18, 2012 Dennis Sweitzer, Ph.D., Principal Biostatistician Medidata Randomization Center of Excellence
More informationSaunders, O 1, Asseburg, C 2, O Reilly, K 3, Sly, I 1, Lee, D 1
Modelling Alzheimer s disease progression using a multivariate model for the associated outcomes of cognition, behaviour and functioning: Data from the ICTUS Study Saunders, O 1, Asseburg, C, O Reilly,
More informationUniversity of Wollongong. Research Online. Australian Health Services Research Institute
University of Wollongong Research Online Australian Health Services Research Institute Faculty of Business 2011 Measurement of error Janet E. Sansoni University of Wollongong, jans@uow.edu.au Publication
More informationICH E9(R1) Technical Document. Estimands and Sensitivity Analysis in Clinical Trials STEP I TECHNICAL DOCUMENT TABLE OF CONTENTS
ICH E9(R1) Technical Document Estimands and Sensitivity Analysis in Clinical Trials STEP I TECHNICAL DOCUMENT TABLE OF CONTENTS A.1. Purpose and Scope A.2. A Framework to Align Planning, Design, Conduct,
More informationIAPT: Regression. Regression analyses
Regression analyses IAPT: Regression Regression is the rather strange name given to a set of methods for predicting one variable from another. The data shown in Table 1 and come from a student project
More informationSequence balance minimisation: minimising with unequal treatment allocations
Madurasinghe Trials (2017) 18:207 DOI 10.1186/s13063-017-1942-3 METHODOLOGY Open Access Sequence balance minimisation: minimising with unequal treatment allocations Vichithranie W. Madurasinghe Abstract
More informationAdjusted Crash Odds Ratio Estimates of Driver Behavior Errors: A Re-Analysis of the SHRP2 Naturalistic Driving Study Data
University of Iowa Iowa Research Online Driving Assessment Conference 2017 Driving Assessment Conference Jun 28th, 12:00 AM Adjusted Crash Odds Ratio Estimates of Driver Behavior Errors: A Re-Analysis
More informationGSK Medicine: Study Number: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationSupplementary Online Content
Supplementary Online Content Lingvay I, Manghi FP, García-Hernández P, et al. Effect of insulin glargine up-titration vs insulin degludec/liraglutide on glycated hemoglobin levels in patients with type
More information2.0 Synopsis. Adalimumab R&D/04/118. (For National Authority Use Only) Referring to Part of Dossier: Volume:
2.0 Synopsis Abbott Laboratories Name of Study Drug: Adalimumab Name of Active Ingredient: Adalimumab Title of Study: Individual Study Table Referring to Part of Dossier: Volume: Page: (For National Authority
More informationEstimands, Missing Data and Sensitivity Analysis: some overview remarks. Roderick Little
Estimands, Missing Data and Sensitivity Analysis: some overview remarks Roderick Little NRC Panel s Charge To prepare a report with recommendations that would be useful for USFDA's development of guidance
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
Study No.: 29060/717 Title: A Double-Blind, Placebo-Controlled, 3-Arm, Fixed-Dose Study of CR Intermittent Dosing (12.5 mg and 25 mg) for Premenstrual Dysphoric Disorder Rationale: In most trials investigating
More informationCritical Appraisal Series
Definition for therapeutic study Terms Definitions Study design section Observational descriptive studies Observational analytical studies Experimental studies Pragmatic trial Cluster trial Researcher
More informationProtocol. This trial protocol has been provided by the authors to give readers additional information about their work.
Protocol This trial protocol has been provided by the authors to give readers additional information about their work. Protocol for: Howard R, McShane R, Lindesay J, et al. Donepezil and memantine for
More informationOnline Supplementary Material
Section 1. Adapted Newcastle-Ottawa Scale The adaptation consisted of allowing case-control studies to earn a star when the case definition is based on record linkage, to liken the evaluation of case-control
More informationLecture 14: Adjusting for between- and within-cluster covariates in the analysis of clustered data May 14, 2009
Measurement, Design, and Analytic Techniques in Mental Health and Behavioral Sciences p. 1/3 Measurement, Design, and Analytic Techniques in Mental Health and Behavioral Sciences Lecture 14: Adjusting
More informationSponsor. Novartis Pharmaceuticals Corporation Generic Drug Name. Agomelatine Therapeutic Area of Trial. Major depressive disorder Approved Indication
Clinical Trial Results Database Page 1 Sponsor Novartis Pharmaceuticals Corporation Generic Drug Name Therapeutic Area of Trial Major depressive disorder Approved Indication Investigational drug Study
More informationDonepezil, galantamine, rivastigmine (review) and memantine for the treatment of Alzheimer s disease (amended)
Issue date: November 2006 (amended September 2007) Review date: September 2009 Donepezil, galantamine, rivastigmine (review) and memantine for the treatment of Alzheimer s disease (amended) Includes a
More informationAppendix K: Evidence review flow charts
K.1 Dementia diagnosis K.1.1 Dementia diagnosis What are the most effective methods of primary assessment to decide whether a person with suspected dementia should be referred to a dementia service? What
More informationChecklist for appraisal of study relevance (child sex offenses)
Appendix 3 Evaluation protocols. [posted as supplied by author] Checklist for appraisal of study relevance (child sex offenses) First author, year, reference number Relevance Yes No Cannot answer Not applicable
More informationA Randomised, Blinded, Placebo-Controlled Trial in Dementia Patients Continuing or Stopping Neuroleptics (The DART-AD Trial)
A Randomised, Blinded, Placebo-Controlled Trial in Dementia Patients Continuing or Stopping Neuroleptics (The DART-AD Trial) Clive Ballard 1*, Marisa Margallo Lana 2, Megan Theodoulou 3, Simon Douglas
More informationThe study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationNursing home placement in the Donepezil and Memantine in Moderate to Severe Alzheimer s Disease (DOMINO-AD) trial: secondary and post-hoc analyses
Nursing home placement in the Donepezil and Memantine in Moderate to Severe Alzheimer s Disease (DOMINO-AD) trial: secondary and post-hoc analyses Robert Howard, Rupert McShane, James Lindesay, Craig Ritchie,
More informationShould individuals with missing outcomes be included in the analysis of a randomised trial?
Should individuals with missing outcomes be included in the analysis of a randomised trial? ISCB, Prague, 26 th August 2009 Ian White, MRC Biostatistics Unit, Cambridge, UK James Carpenter, London School
More informationMEA DISCUSSION PAPERS
Inference Problems under a Special Form of Heteroskedasticity Helmut Farbmacher, Heinrich Kögel 03-2015 MEA DISCUSSION PAPERS mea Amalienstr. 33_D-80799 Munich_Phone+49 89 38602-355_Fax +49 89 38602-390_www.mea.mpisoc.mpg.de
More informationStatistical Analysis Plan
The BALANCED Anaesthesia Study A prospective, randomised clinical trial of two levels of anaesthetic depth on patient outcome after major surgery Protocol Amendment Date: November 2012 Statistical Analysis
More informationStudy funding: Supported by the Medical Research Council (G ) and the UK Alzheimer s Society.
R. Howard, R. McShane, J. Lindesay, C. Ritchie, A. Baldwin, R. Barber, A. Burns, T. Dening, D. Findlay, C. Holmes, R. Jones, Roy Jones, I. McKeith, A. Macharouthu, J. O Brien, B. Sheehan, E. Juszczak,
More informationJ2.6 Imputation of missing data with nonlinear relationships
Sixth Conference on Artificial Intelligence Applications to Environmental Science 88th AMS Annual Meeting, New Orleans, LA 20-24 January 2008 J2.6 Imputation of missing with nonlinear relationships Michael
More informationPharmaceutical Statistics Journal Club 15 th October Missing data sensitivity analysis for recurrent event data using controlled imputation
Pharmaceutical Statistics Journal Club 15 th October 2015 Missing data sensitivity analysis for recurrent event data using controlled imputation Authors: Oliver Keene, James Roger, Ben Hartley and Mike
More informationG , G , G MHRN
Estimation of treatment-effects from randomized controlled trials in the presence non-compliance with randomized treatment allocation Graham Dunn University of Manchester Research funded by: MRC Methodology
More informationUsing Statistical Principles to Implement FDA Guidance on Cardiovascular Risk Assessment for Diabetes Drugs
Using Statistical Principles to Implement FDA Guidance on Cardiovascular Risk Assessment for Diabetes Drugs David Manner, Brenda Crowe and Linda Shurzinske BASS XVI November 9-13, 2009 Acknowledgements
More informationSmall-area estimation of mental illness prevalence for schools
Small-area estimation of mental illness prevalence for schools Fan Li 1 Alan Zaslavsky 2 1 Department of Statistical Science Duke University 2 Department of Health Care Policy Harvard Medical School March
More informationSYNOPSIS. Risperidone-R064766: Clinical Study Report RIS-INT-24 (FOR NATIONAL AUTHORITY USE ONLY)
SYNOPSIS Protocol No.: RIS-INT-24 Psychosis in Alzheimer s disease (PAD) analysis Title of Study: Risperidone in the treatment of behavioral disturbances in demented patients: an international, multicenter,
More informationPrinciples and Methods of Intervention Research
Principles and Methods of Intervention Research NVVO, February 2, 2009 Jan G.P. Tijssen, Ph.D. Academic Medical Center - University of Amsterdam Introduction Pathophysiologic and pharmacological insight
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationSupplementary Online Content
1 Supplementary Online Content Friedman DJ, Piccini JP, Wang T, et al. Association between left atrial appendage occlusion and readmission for thromboembolism among patients with atrial fibrillation undergoing
More informationConfounding by indication developments in matching, and instrumental variable methods. Richard Grieve London School of Hygiene and Tropical Medicine
Confounding by indication developments in matching, and instrumental variable methods Richard Grieve London School of Hygiene and Tropical Medicine 1 Outline 1. Causal inference and confounding 2. Genetic
More informationOnline Appendices Online Appendix 1 Online Appendix 2 Online Appendix 3a Online Appendix 3b Online Appendix 3c Online Appendix 4 Online Appendix 5
Online Appendices Online Appendix 1 Search terms used to identify studies Online Appendix 2 The identification process for eligible studies Online Appendix 3a- Niacin, Risk of bias table Online Appendix
More informationA re-randomisation design for clinical trials
Kahan et al. BMC Medical Research Methodology (2015) 15:96 DOI 10.1186/s12874-015-0082-2 RESEARCH ARTICLE Open Access A re-randomisation design for clinical trials Brennan C Kahan 1*, Andrew B Forbes 2,
More informationAP Statistics Exam Review: Strand 2: Sampling and Experimentation Date:
AP Statistics NAME: Exam Review: Strand 2: Sampling and Experimentation Date: Block: II. Sampling and Experimentation: Planning and conducting a study (10%-15%) Data must be collected according to a well-developed
More informationClinical trials with incomplete daily diary data
Clinical trials with incomplete daily diary data N. Thomas 1, O. Harel 2, and R. Little 3 1 Pfizer Inc 2 University of Connecticut 3 University of Michigan BASS, 2015 Thomas, Harel, Little (Pfizer) Clinical
More informationPATCH Analysis Plan v1.2.doc Prophylactic Antibiotics for the Treatment of Cellulitis at Home: PATCH Analysis Plan for PATCH I and PATCH II Authors: Angela Crook, Andrew Nunn, James Mason and Kim Thomas,
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Navari RM, Qin R, Ruddy KJ, et al. for the prevention of chemotherapy-induced
More informationComparison of imputation and modelling methods in the analysis of a physical activity trial with missing outcomes
IJE vol.34 no.1 International Epidemiological Association 2004; all rights reserved. International Journal of Epidemiology 2005;34:89 99 Advance Access publication 27 August 2004 doi:10.1093/ije/dyh297
More informationEstimands and Sensitivity Analysis in Clinical Trials E9(R1)
INTERNATIONAL CONCIL FOR HARMONISATION OF TECHNICAL REQUIREMENTS FOR PHARMACEUTICALS FOR HUMAN USE ICH HARMONISED GUIDELINE Estimands and Sensitivity Analysis in Clinical Trials E9(R1) Current Step 2 version
More informationAppendix 1. Sensitivity analysis for ACQ: missing value analysis by multiple imputation
Appendix 1 Sensitivity analysis for ACQ: missing value analysis by multiple imputation A sensitivity analysis was carried out on the primary outcome measure (ACQ) using multiple imputation (MI). MI is
More informationLecture 2. Key Concepts in Clinical Research
Lecture 2 Key Concepts in Clinical Research Outline Key Statistical Concepts Bias and Variability Type I Error and Power Confounding and Interaction Statistical Difference vs Clinical Difference One-sided
More informationAnalysis of TB prevalence surveys
Workshop and training course on TB prevalence surveys with a focus on field operations Analysis of TB prevalence surveys Day 8 Thursday, 4 August 2011 Phnom Penh Babis Sismanidis with acknowledgements
More informationGuselkumab (plaque psoriasis)
IQWiG Reports Commission No. A18-24 Guselkumab (plaque psoriasis) Addendum to Commission A17-60 1 Addendum Commission: A18-24 Version: 1.0 Status: 27 April 2018 1 Translation of addendum A18-24 Guselkumab
More informationBLISTER STATISTICAL ANALYSIS PLAN Version 1.0
The Bullous Pemphigoid Steroids and Tetracyclines (BLISTER) Study EudraCT number: 2007-006658-24 ISRCTN: 13704604 BLISTER STATISTICAL ANALYSIS PLAN Version 1.0 Version Date Comments 0.1 13/01/2011 First
More informationExamining Relationships Least-squares regression. Sections 2.3
Examining Relationships Least-squares regression Sections 2.3 The regression line A regression line describes a one-way linear relationship between variables. An explanatory variable, x, explains variability
More informationEffective Implementation of Bayesian Adaptive Randomization in Early Phase Clinical Development. Pantelis Vlachos.
Effective Implementation of Bayesian Adaptive Randomization in Early Phase Clinical Development Pantelis Vlachos Cytel Inc, Geneva Acknowledgement Joint work with Giacomo Mordenti, Grünenthal Virginie
More informationSection on Survey Research Methods JSM 2009
Missing Data and Complex Samples: The Impact of Listwise Deletion vs. Subpopulation Analysis on Statistical Bias and Hypothesis Test Results when Data are MCAR and MAR Bethany A. Bell, Jeffrey D. Kromrey
More informationSYNOPSIS 2/198 CSR_BDY-EFC5825-EN-E02. Name of company: TABULAR FORMAT (For National Authority Use only)
SYNOPSIS Title of the study: A randomized, double-blind, placebo-controlled, parallel-group, fixed-dose (rimonabant 20 mg) multicenter study of long-term glycemic control with rimonabant in treatment-naïve
More informationPlease Join Us. International Psychogeriatric Association. Dependency Ratio. Geriatric Psychiatry in the 21st Century: A Global Perspective
International Psychogeriatric Association Please Join Us Geriatric Psychiatry in the 21st Century: A Global Perspective Jacobo Mintzer M.D. Executive Director Roper Saint Frances Clinical and Biotechnology
More informationClinical Study Synopsis for Public Disclosure
abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis - which is part of
More informationLead team presentation: Roflumilast for treating chronic obstructive pulmonary disease [ID984]
Lead team presentation: Roflumilast for treating chronic obstructive pulmonary disease [ID984] 1 st Appraisal Committee meeting Background & Clinical Effectiveness John McMurray 11 th January 2016 For
More information2. SYNOPSIS Name of Sponsor/Company:
in patients with refractory partial seizures 14 Jun 2007 2. SYNOPSIS TITLE OF STUDY: Efficacy and safety of BIA 2-093 as adjunctive therapy for refractory partial seizures in a double-blind, randomized,
More informationSYNOPSIS. Drug substance(s) Budesonide/formoterol Document No. Edition No. Study code SD Date 16 December 2004
Drug product SYMBICORT pmdi 160/4.5 µg SYNOPSIS Drug substance(s) Budesonide/formoterol Document No. Edition No. Date 16 December 2004 A Twelve-Week, Randomized, Double-Blind, Double-Dummy, Placebo-Controlled
More informationControversies in Clinical Trials. Pirfenidone for Idiopathic Pulmonary Fibrosis (IPF)
Controversies in Clinical Trials Pirfenidone for Idiopathic Pulmonary Fibrosis (IPF) Controversies to be highlighted by IPF Post-hoc analyses Story Primary end point selection Changing prespecified endpoints
More informationClinialTrials.gov Identifier: Sponsor/company: sanofi-aventis
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription Sponsor/company: sanofi-aventis ClinialTrials.gov
More informationPFIZER INC. THERAPEUTIC AREA AND FDA APPROVED INDICATIONS: See United States Package Insert (USPI)
PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert. For publications based on this study, see associated bibliography.
More informationGSK Medicine: Study Number: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objective:
GSK Medicine: abacavir (ABC)/dolutegravir (DTG)/lamivudine (3TC) Study Number: 201147 Title: A IIIb, randomized, open-label study of the safety, efficacy, and tolerability of switching to a fixed-dose
More informationFinland and Sweden and UK GP-HOSP datasets
Web appendix: Supplementary material Table 1 Specific diagnosis codes used to identify bladder cancer cases in each dataset Finland and Sweden and UK GP-HOSP datasets Netherlands hospital and cancer registry
More informationBEST PRACTICES FOR IMPLEMENTATION AND ANALYSIS OF PAIN SCALE PATIENT REPORTED OUTCOMES IN CLINICAL TRIALS
BEST PRACTICES FOR IMPLEMENTATION AND ANALYSIS OF PAIN SCALE PATIENT REPORTED OUTCOMES IN CLINICAL TRIALS Nan Shao, Ph.D. Director, Biostatistics Premier Research Group, Limited and Mark Jaros, Ph.D. Senior
More informationAppendix L: Research recommendations
1 L.1 Dementia diagnosis (amyloid PET imaging) recommendation 1 Index Test Reference Test(s) Does amyloid PET imaging provide additional diagnostic value, and is it cost effective, for the diagnosis of
More informationTransmission to CHMP July Adoption by CHMP for release for consultation 20 July Start of consultation 31 August 2017
1 2 3 30 August 2017 EMA/CHMP/ICH/436221/2017 Committee for Human Medicinal Products 4 ICH E9 (R1) addendum on estimands and sensitivity 5 analysis in clinical trials to the guideline on statistical 6
More informationStatistical Analysis Plan (SAP):
Version 1 Page 1 (SAP): The study A multi-site RCT comparing regional and general anaesthesia for effects on neurodevelopmental outcome and apnoea in infants Analysis of the five year follow up data Author(s):
More informationRegression Discontinuity Design
Regression Discontinuity Design Regression Discontinuity Design Units are assigned to conditions based on a cutoff score on a measured covariate, For example, employees who exceed a cutoff for absenteeism
More information